Test ID: GID2    
Autoimmune Gastrointestinal Dysmotility Evaluation, Serum

Investigating unexplained weight loss, early satiety, anorexia, nausea, vomiting, constipation or diarrhea in a patient with past or family history of cancer or autoimmunity

Directing a focused search for cancer

Investigating gastrointestinal symptoms that appear in the course or wake of cancer therapy, not explainable by recurrent cancer, metastasis or therapy; detection of autoantibodies on this profile helps differentiate autoimmune gastrointestinal dysmotility from the effects of chemotherapy

Detecting early evidence of cancer recurrence in previously seropositive patients who have a rising titer of 1 or more autoantibodies

If immunofluorescence assay (IFA) patterns suggest collapsin response-mediator protein-5-IgG (CRMP-5-IgG), then CRMP-5-IgG IFA or Western blot is performed at an additional charge.

If IFA patterns suggest amphiphysin antibody, then amphiphysin titer and/or amphiphysin immunoblot is performed at an additional charge.

If IFA pattern suggests ANNA-1 antibody, then ANNA-1 immunoblot and ANNA-2 immunoblot is performed at an additional charge.

If IFA pattern suggests PCA-1 antibody, then PCA-1 IFA and immunoblot is performed at an additional charge.

If IFA pattern suggests PCA-2 antibody, then PCA-2 IFA performed at an additional charge.

If IFA pattern suggests PCA-Tr antibody, then PCA-Tr IFA and immunoblot is performed at an additional charge.

If IFA pattern suggests NMDA-R, then NMDA-R cell-binding assay (CBA) and NMDA-R titer are performed at an additional charge.

If IFA pattern suggests AMPA-R, then AMPA-R CBA and AMPA-R titer are performed at an additional charge.

If IFA pattern suggests GABA-B-R, then GABA-B-R CBA and GABA-B-R titer are performed at an additional charge.

If IFA pattern suggests DPPX antibody, then DPPX CBA and DPPX titer are performed at an additional charge.

If IFA pattern suggests mGluR1 antibody, then mGluR1 CBA and mGluR1 titer are performed at an additional charge.

If acetylcholine (ACh) receptor binding antibody is above 0.02 nmol/L, then ACh receptor modulating antibodies and CRMP-5-IgG Western blot are performed at an additional charge.

If VGKC is above 0.00 nmol/L, then LGI1-IgG CBA and CASPR2-IgG CBA are performed at an additional charge.

See Autoimmune Gastrointestinal Dysmotility Evaluation Algorithm in Special Instructions.

• Autoimmune Gastrointestinal Dysmotility Evaluation Algorithm

AMPHS, AMPIS, ANN1S, CRMS, DPPIS, DPPTS, GABIS, NMDIS, PCAB2, PCABP, PCATR: Indirect Immunofluorescence Assay (IFA)

AMPCS, CS2CS, DPPCS, GABCS, LG1CS, NMDCS: Cell Binding Assay (CBA)

ARMO: Live Cell Assay (LCA)

CRMWS: Western Blot (WB)

AMIBS, AN1BS, AN2BS, PC1BS, PCTBS: Immunoblot (IB)

ARBI, CCN, GANG, GD65S, VGKC: Radioimmunoassay (RIA)

STR: Enzyme-Linked Immunosorbent Assay (ELISA)